CN112979751B - Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof - Google Patents
Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof Download PDFInfo
- Publication number
- CN112979751B CN112979751B CN201911216154.3A CN201911216154A CN112979751B CN 112979751 B CN112979751 B CN 112979751B CN 201911216154 A CN201911216154 A CN 201911216154A CN 112979751 B CN112979751 B CN 112979751B
- Authority
- CN
- China
- Prior art keywords
- dioxane
- carboline
- tetrahydro
- formyl
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 10
- 230000002194 synthesizing effect Effects 0.000 claims description 14
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 13
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 claims description 9
- NQKRILCJYCASDV-QWRGUYRKSA-N His-Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 NQKRILCJYCASDV-QWRGUYRKSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 239000007791 liquid phase Substances 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 3
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 21
- 229940124599 anti-inflammatory drug Drugs 0.000 abstract description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 27
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000000243 solution Substances 0.000 description 21
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 18
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 16
- 206010061218 Inflammation Diseases 0.000 description 16
- 230000004054 inflammatory process Effects 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 11
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 8
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 8
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 8
- 239000011780 sodium chloride Substances 0.000 description 8
- 238000001914 filtration Methods 0.000 description 7
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 7
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 230000008034 disappearance Effects 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 5
- 230000006020 chronic inflammation Effects 0.000 description 5
- 208000037976 chronic inflammation Diseases 0.000 description 5
- 210000005069 ears Anatomy 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- 206010014025 Ear swelling Diseases 0.000 description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 4
- PAYJYEZMAOJHHD-DAFXYXGESA-N OCC(CO)(C1=NC2=CC=CC=C2C1C1)N[C@@H]1C(OCC1=CC=CC=C1)=O Chemical compound OCC(CO)(C1=NC2=CC=CC=C2C1C1)N[C@@H]1C(OCC1=CC=CC=C1)=O PAYJYEZMAOJHHD-DAFXYXGESA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000003208 petroleum Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 3
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 3
- 208000017667 Chronic Disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 229960001138 acetylsalicylic acid Drugs 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000009833 condensation Methods 0.000 description 3
- 230000005494 condensation Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- IKAIKUBBJHFNBZ-LURJTMIESA-N Gly-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)CN IKAIKUBBJHFNBZ-LURJTMIESA-N 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- WFDXYGGWXJNVOU-QHCPKHFHSA-N benzyl (2s)-2-[[2-[(2-methylpropan-2-yl)oxycarbonylamino]acetyl]amino]-6-(phenylmethoxycarbonylamino)hexanoate Chemical compound C([C@H](NC(=O)CNC(=O)OC(C)(C)C)C(=O)OCC=1C=CC=CC=1)CCCNC(=O)OCC1=CC=CC=C1 WFDXYGGWXJNVOU-QHCPKHFHSA-N 0.000 description 2
- TYQYRKDGHAPZRF-INIZCTEOSA-N benzyl (2s)-2-amino-3-(1h-indol-3-yl)propanoate Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)OCC1=CC=CC=C1 TYQYRKDGHAPZRF-INIZCTEOSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 108010015792 glycyllysine Proteins 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical compound C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229910000343 potassium bisulfate Inorganic materials 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229940026510 theanine Drugs 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- -1 15/1) Chemical compound 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 229920002449 FKM Polymers 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000010936 aqueous wash Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000028327 extreme fatigue Diseases 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007472 neurodevelopment Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 239000002441 uremic toxin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
The invention discloses 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys with The following formula, discloses a preparation method thereof and discloses anti-inflammatory activity thereof. Thus discloses the application of the compound in preparing anti-inflammatory drugs.
Description
Technical Field
The invention relates to a 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys compound, a preparation method thereof and anti-inflammatory activity thereof. The invention thus relates to the use of such compounds in anti-inflammatory medicaments.
Background
The 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid is a pharmacophore with multiple biological activities, and the theanine is also the pharmacophore with multiple biological activities. In a related invention, The inventor discloses that 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid and theanine are fused to form 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The with The left formula, and The 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The has The function of resisting tumors. The inventor realizes that The 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The following formula generated by introducing uremic toxin tripeptide His-Gly-Lys into The carboxyl terminal of The 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys has stronger antitumor effect. Further studies led the inventors to find that they also have anti-inflammatory effects.
Inflammation is the cause of many diseases. Among a range of diseases triggered by inflammation, fibrosis is one of the most important diseases. For example, inflammation of the central nervous system can trigger brain fibrosis. Cancer metastasis is another fatal disease triggered by inflammation. The proportion of deaths due to metastasis in dead cancer patients is up to 90%. Chronic inflammation of the brain may be associated with the onset of various metabolic diseases, such as obesity and diabetes. In connection with the brain, inflammation can cause a variety of common mental disorders. Coronary inflammation or chronic inflammation of blood vessels is associated with atherosclerotic cardiovascular disease. Another fatal problem of chronic inflammation is associated with the pathogenesis of a variety of tumors. For example, chronic inflammation is associated with the onset of colon cancer. Although the molecular mechanism is not clear, a large number of relationships between inflammation and affective disorders have been reported. Inflammation has long been recognized as a mechanism for triggering and sustaining depression, chronic pain, and long-term extreme fatigue. Inflammation plays a central role, for example, in behavioral and emotional changes in patients with liver disease. Inflammation can trigger premature birth and parturition. Perinatal inflammation can compromise the physiology and behavior of the mature brain. Systemic inflammation can affect neurological development. By affecting the immune system, chronic inflammation in the long term can damage the host. Physical aging is the strongest risk factor for most chronic diseases, causing several chronic diseases to be combined into a whole. Inflammation is a trigger for a combination of several chronic diseases. Senile tuberculosis is associated with a basal inflammatory state. In addition, inflammation is also associated with dementia. As such, the development of a drug for preventing and treating inflammation without toxic and side effects has been increasingly appreciated. Despite the great efforts that have been made, no substantial progress has been made.
The inventor realizes that The 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys with The right formula has The anti-inflammatory effect and contributes to research and development of anti-inflammatory drugs. Based on this knowledge, the inventors have proposed the present invention.
Disclosure of Invention
The first aspect of The present invention provides 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys of The formula.
The second content of The invention is to provide a preparation method of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys, which comprises The following steps:
1) synthesizing (3S) -1, 1-dihydroxymethyl-tetrahydro-beta-carboline-3-benzyl carboxylate;
2) synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-benzyl carboxylate;
3) synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid;
4) synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-OBzl by adopting a liquid phase condensation method with Dicyclohexylcarbodiimide (DCC) as a condensing agent and 1-hydroxybenzotriazole (HOBt) as a catalyst;
5) synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The;
6) synthesizing HCl, His-Gly-Lys (Z) -OBzl by adopting a liquid phase condensation method with DCC as a condensing agent and HOBt as a catalyst;
7) synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys (Z) -OBzl by a liquid phase condensation method with DCC as a condensing agent and HOBt as a catalyst;
8) synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys;
the third aspect of The present invention is to evaluate The anti-inflammatory effect of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiroyl) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys.
Drawings
FIG. 1. synthetic route of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys: i) trifluoroacetic acid, 1, 3-dihydroxyacetone; ii) concentrated sulfuric acid, acetone; iii) Palladium on carbon (Pd), H2(ii) a iv) Dicyclohexylcarbodiimide (DCC), 1-hydroxybenzotriazole (HOBt), N-methylmorpholine (NMM); v) a solution of hydrogen chloride in ethyl acetate (4M).
Detailed Description
To further illustrate the invention, a series of examples are given below. These examples are purely illustrative and are intended to be a detailed description of the invention only and should not be taken as limiting the invention.
EXAMPLE 1 preparation of benzyl (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-carboxylate (1)
2g (7.2mmol) of L-tryptophan benzyl ester was added to 10mL of dichloromethane, and the mixture was sufficiently stirred to dissolve it. Under ice-bath conditions, 1mL of trifluoroacetic acid was slowly added dropwise to the solution. Then, 0.78g (8.6mmol) of 1, 3-dihydroxyacetone was added to the solution and reacted at room temperature for 7 hours. TLC showed disappearance of L-tryptophan benzyl ester (dichloromethane/methanol: 30: 1). Under ice-bath conditions, 50mL of saturated NaHCO was added to the solution3The solution was stirred well, then a dichloromethane layer was left, followed by saturated NaHCO3The solution (30 mL. times.3) was washed with saturated NaCl solution (30 mL. times.3), and the dichloromethane layer was dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave 2.03g (77%) of the title compound as a yellow powder. ESI-MS (M/e):367[ M + H]+。
Example 2 preparation of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-carboxylic acid benzyl ester (2) to 5mL of anhydrous acetone was added 0.2g (0.55mmol) of (3S) -1, 1-dihydroxymethyl-tetrahydro- β -carboline-3-carboxylic acid benzyl ester (1). 100. mu.L of concentrated sulfuric acid was added thereto under ice-bath conditions, followed by stirring at room temperature for 3 hours. TLC showed the disappearance of compound 1 (petroleum ether/ethyl acetate, 4: 1). Under ice-bath conditions, saturated NaHCO was used3Adjusting pH of the reaction solution to 7, concentrating the obtained solution under reduced pressure to remove acetone, extracting and washing the residue with ethyl acetate for 3 times, and saturating ethyl acetate layerThe NaCl solution was washed to neutrality. The ethyl acetate layer was dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave a tan solid which was separated by column chromatography (petroleum ether/ethyl acetate, 4:1) to give 0.08g (35.8%) of the title compound as a white solid. ESI-MS (M/e):407[ M + H]+。
EXAMPLE 3 preparation of 3S-1- (1, 1-dimethyl-1, 3-dioxan-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid (3)
To 10mL of methanol were added 0.20g (0.5mmol) of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-carboxylic acid benzyl ester (2) and 0.02g of Pd/C. Stirring and passage of 12h hydrogen, TLC showed disappearance of Compound 2 (petroleum ether/ethyl acetate, 4: 1). The palladium-carbon (Pd/C) was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was triturated with ether to give 0.14g (90%) of the title compound as a colourless solid. ESI-MS (M/e) 317[ M + H ]]+。
EXAMPLE 4 preparation of 3S-1- (1, 1-dimethyl-1, 3-dioxan-6-spiroyl) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-OBzl (4)
To 20mL of tetrahydrofuran were added 0.19g (0.6mmol) of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-carboxylic acid (3), 0.15g (0.72mmol) of N, N' -Dicyclohexylcarbodiimide (DCC) and 0.09g (0.72mmol) of 1-hydroxybenzotriazole (HOBt). Stir for 30 minutes in an ice bath. Then, 0.20g (0.66mmol) of HCl. The-OBzl was added to The reaction mixture. Subsequently, N-methylmorpholine (NMM) was added dropwise to the reaction mixture to adjust the pH of the reaction mixture to 9. After stirring at room temperature for 6 hours, TLC showed the disappearance of compound 3 (dichloromethane/methanol, 30/1). Dicyclohexylurea (DCU) was filtered off, the filtrate was concentrated under reduced pressure, the residue obtained was dissolved in 30mL of ethyl acetate, and the solution was filtered again to remove DCU. The filtrate was sequentially treated with 5% NaHCO3Aqueous extraction (15 mL. times.3), saturated aqueous NaCl solution (15 mL. times.3), 5% KHSO4Aqueous wash (15 mL. times.3), saturated aqueous NaCl wash (15 mL. times.3), 5% NaHCO3The mixture was washed with an aqueous solution (15 mL. times.3) and with a saturated aqueous NaCl solution (15 mL. times.3), and dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave a yellow powder which was purified by silica gel column chromatography (petroleum ether/ethyl acetate, 10/1) to give 0.27g (80%) of the title compound as a colourless powderAnd (3) grinding. ESI-MS (M/e):563[ M + H]+；1H-NMR(300MHz,DMSO-d6):δ/ppm＝10.94(s,1H),8.28(t,J＝7.2Hz,1H),7.79(s,1H),7.37(m,6H),7.07(m,1H),7.02(m,1H),5.16(s,1H),5.12(s,1H),4.40(m,1H),4.21(m,1H),3.99(m,1H),3.75(m,1H),3.61(m,2H),3.02(m,2H),2.12(m,2H),1.82(m,2H),1.65(s,3H),1.42(s,3H),1.22(m,2H),1.01(m,3H)。
EXAMPLE 5 preparation of 3S-1- (1, 1-dimethyl-1, 3-dioxan-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The (5)
To 10mL of methanol were added 0.28g (0.5mmol) of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-OBzl (4) and 0.02g of palladium on carbon (Pd/C). Stirring and passage of 12h hydrogen, TLC showed disappearance of compound 4 (dichloromethane/methanol, 30/1). Pd/C was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was triturated with ether to give 0.21g (90%) of the title compound as a yellow solid. ESI-MS (M/e):473[ M + H]+，1H-NMR(300MHz,DMSO-d6):δ/ppm＝10.98(s,1H),8.18(d,J＝7.5Hz,1H),7.79(s,1H),7.40(dt,J1＝4.8Hz,J2＝8.1Hz,2H),7.02(td,J1＝8.1Hz,J2＝4.8Hz,2H),4.40(m,1H),4.28(m,1H),4.12(m,1H),4.02(m,1H),3.81(m,1H),3.61(m,1H),3.02(m,2H),2.14(m,2H),1.82(m,2H),1.65(s,3H),1.41(s,3H),1.22(m,2H),1.03(m,3H)。
EXAMPLE 6 preparation of Boc-Gly-Lys (Z) -OBzl
Using the method of example 4, 2.12g (80%) of the title compound was obtained as a colorless solid from 0.96g (5.5mmol) of Boc-Gly and 1.85g (5mmol) of Hcl.Lys (z) -OBzl.
EXAMPLE 7 preparation of HCl.Gly-Lys (Z) -OBzl
1.58g (3mmol) of Boc-Gly-Lys (z) -OBzl was dissolved in 20mL of hydrogen chloride in ethyl acetate (4M) and reacted for 4 hours in ice bath. TLC monitoring indicated complete reaction (dichloromethane/methanol system, 30/1). The reaction mixture was concentrated under reduced pressure, the residue was dissolved in anhydrous ethyl acetate, and the resulting solution was concentrated under reduced pressure. This operation was repeated 3 times. The resulting white powdery substance was sufficiently washed with dehydrated ether to obtain 1.32g (95%) of the title compound as a colorless solid.
Example 8 preparation of Boc-His (Boc) -Gly-Lys (Z) -OBzl
From 1.77g (5mmol) Boc-His (Boc) and 2.78g (6mmol) HCl Gly-Lys (z) -OBzl 2.56g (67%) of the title compound were obtained as colorless solid using the method of example 4. ESI-MS (M/e) 765[ M + H ] +.
EXAMPLE 9 preparation of HCl His-Gly-Lys (Z) -OBzl
From 2.29g (3mmol) Boc-His (Boc) -Gly-Lys (z) -OBzl 1.66g (92%) of the title compound was obtained as colorless solid using the method of example 7.
EXAMPLE 10 preparation of 3S-1- (1, 1-dimethyl-1, 3-dioxan-6-spiroyl) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys (Z) -OBzl (6)
To 30mL of anhydrous tetrahydrofuran were added 0.47g (1mmol) of (3S) -1-bis (methyl) -mono, tris-dioxane-tetrahydro- β -carboline-3-formyl-The (5), 0.25g (1.2mmol) of DCC and 0.16g (1.2mmol) of HOBt, and The mixture was stirred for 30 minutes in an ice bath. Then, 0.66g (2.2mmol) of HCl. His-Gly-Lys (z) -OBzl was added to the reaction mixture. N-methylmorpholine (NMM) was added dropwise to adjust the pH of the reaction mixture to 9. The reaction was carried out at room temperature for 8 hours. TLC showed compound 5 to disappear (dichloromethane/methanol, 15/1), Dicyclohexylurea (DCU) was filtered off and the filtrate was concentrated under reduced pressure. The residue was dissolved in 100mL of ethyl acetate and the solution was filtered to remove DCU. The filtrate was washed with a 5% aqueous NaHCO3 solution (30 mL. times.3), a saturated aqueous NaCl solution (30 mL. times.3), a 5% aqueous KHSO4 solution (30 mL. times.3), a saturated aqueous NaCl solution (30 mL. times.3), a 5% aqueous NaHCO3 solution (30 mL. times.3), a saturated aqueous NaCl solution (30 mL. times.3), and dried over anhydrous sodium sulfate for 12 hours. Filtration and concentration of the filtrate under reduced pressure gave a yellow powder which was purified by silica gel column chromatography (dichloromethane/methanol, 15/1) to give 0.71g (70%) of the title compound as a yellow powder. ESI-MS (M/e) 1020[ M + H ] +; 1H-NMR (300MHz, DMSO-d6): δ/ppm ═ 10.93(s,1H),8.53(m,1H),8.24(m,1H),8,11(m,1H),8.03(m,1H),7.76(m,1H),7.55(s,1H),7.34(m,11H),7.19(m,1H),7.06(m,1H),6.98(m,1H),6.89(s,1H),5.12(s,2H),4.99(s,2H),4.47(m,1H),4.43-4.28(m,2H),4.00(m,1H),3.89-3.78(m,2H),3.68-3.51(m,4H),3.08-2.93(m,6H),2.12(m,2H), 1H), 1.67(m, 1H), 1.18H, 18H, 1H, 18H, 2H, 1H, 18H, 1H, 18H, 1H, 18H, 1H, 18H, 1H, 18H, 1H, 18H, 1H, 2H, 18H, 1H, 18H, 1H, 18H, 1H, 18H, 1H, 2H, 18H, 1H, 18H, 1H, and the like, 3H) in that respect
EXAMPLE 11 preparation of 3S-1- (1, 1-dimethyl-1, 3-dioxan-6-spiroyl) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys (7)
To 10mL of methanol were added 0.05g (0.05mmol) of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-lys (z) -OBzl (6) and 0.005g Pd/C, stirred and hydrogen was supplied for 12 hours, and TLC showed disappearance of compound 6 (ethyl acetate: water: glacial acetic acid ═ 4:1: 1). The palladium-carbon (Pd/C) was removed by filtration, and the filtrate was concentrated under reduced pressure. The residue was triturated with ether to give 0.035g (90%) of the title compound as a colorless solid. ESI-MS (M/e):795[ M-H]-，1H-NMR(300MHz,DMSO-d6):δ/ppm＝10.98(s,1H),8.41(m,1H),8.26(m,1H),8.07(m,1H),7.92(m,2H),7.52(m,1H),7.40(m,2H),7.00(m,2H),6.86(m,1H),4.47(m,1H),4.41(m,1H),4.38(m,1H),3.99(m,2H),3.77(m,2H),3.64(m,3H),3.04(m,4H),2.73(m,2H),2.12(m,2H),1.74(m,2H),1.61(s,3H),1.50(m,2H),1.38(s,3H),1.23(m,4H),1.00(t,J＝7.2Hz,3H).13C-NMR(125MHz,DMSO-d6):δ/ppm＝173.25,171.82,171.58,136.54,126.70,119.10,111.75,109.04,98.13,52.94,51.58,33.79,32.24,28.37,28.19,27.09,25.79,24.93,22.44,20.21,15.20。
EXAMPLE 12 evaluation of anti-inflammatory Activity of Compound 7
Experimental animals:
ICR mice, male, 20 + -2 g, purchased from Experimental animals technology, Inc., Viton, Beijing.
Administration dose and administration mode:
the oral dosage of The compound 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys (compound 7) is 0.23 mu mol/kg, The oral dosage of positive control aspirin is 1.1mmol/kg, and The negative control is normal saline.
The experimental method comprises the following steps: the ICR induced ear swelling model was used for the experiment.
And (3) experimental operation:
the newly arrived mice were allowed to rest for one day and then randomly grouped, 12 mice per group. And (3) performing intragastric administration on the mice by adopting a sequential method, wherein 6 mice are taken in each group at intervals of 5min, the administration is performed according to a specified dose, after half an hour, the mice are sequentially fixed according to the intragastric sequence, the right ears of the mice are exposed, 30 mu L of dimethylbenzene is uniformly smeared at the edge of the auricle of the right ear of each mouse by using a liquid transfer gun, and the model is built after the dimethylbenzene is naturally volatilized. After coating xylene, the mice had restlessness and red and swollen right ears. Two hours after the model building, the mouse is anesthetized by ether, the mouse is killed by removing the neck, ears at two sides of the mouse are cut along the root part, the edges of the ears are overlapped together, two round ear sheets with the same area and the same size of the two ears are punched by an electric ear swelling ear punching device (model: YLS025A) with the diameter of 7mm, and the two round ear sheets are respectively weighed, wherein the ear swelling degree is the difference value of the two ear weights.
The experimental results are as follows:
swelling degree of ear (right ear weight-left ear weight)
Swelling degree of ear
This is shown followed by statistical comparisons between groups by t-test.
The results are shown in Table 1:
TABLE 1 Activity of Compound 7 for inhibiting tumor Lung metastasis
Note: n is 10, and the test is carried out by t; a) p <0.05 compared to saline group and P >0.05 compared to RGDS group.
The result shows that the ear swelling degree (11.87 +/-2.74 mg) of the mice treated by oral compound 7 under the dosage of 0.23 mu mol/kg has significant difference (14.86 +/-3.26 mg, P <0.05) with the normal saline of the negative control group, and has no significant difference (11.75 +/-4.40 mg, P >0.05) with the aspirin of the positive control group, so that the compound 7 has the activity of inhibiting the mouse inflammation equivalent to that of 1100 mu mol/kg aspirin when the oral dose is as low as 0.23 mu mol/kg, and the invention has prominent technical effect.
Claims (3)
1.3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys of The formula,
2. a process for The synthesis of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys according to claim 1, comprising:
2.1. synthesizing 3S-1,2,3, 4-tetrahydro-beta-carboline-3-benzyl carboxylate;
2.2. synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-benzyl carboxylate;
2.3. synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-carboxylic acid;
2.4. adopting dicyclohexylcarbodiimide as a condensing agent and 1-hydroxybenzotriazole as a catalyst to synthesize 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiroyl) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-OBzl in a liquid phase manner;
2.5. synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The;
2.6. adopting dicyclohexylcarbodiimide as a condensing agent and 1-hydroxybenzotriazole as a catalyst to synthesize HCl, His-Gly-Lys (Z) -OBzl in a liquid phase;
2.7. synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys (Z) -OBzl by using dicyclohexylcarbodiimide as a condensing agent and 1-hydroxybenzotriazole as a catalyst;
2.8. synthesizing 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro-beta-carboline-3-formyl-The-His-Gly-Lys.
3. Use of 3S-1- (1, 1-dimethyl-1, 3-dioxane-6-spiro) -1,2,3, 4-tetrahydro- β -carboline-3-formyl-The-His-Gly-Lys according to claim 1 for The preparation of an anti-inflammatory medicament.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911216154.3A CN112979751B (en) | 2019-12-02 | 2019-12-02 | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911216154.3A CN112979751B (en) | 2019-12-02 | 2019-12-02 | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112979751A CN112979751A (en) | 2021-06-18 |
| CN112979751B true CN112979751B (en) | 2022-04-22 |
Family
ID=76331279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911216154.3A Expired - Fee Related CN112979751B (en) | 2019-12-02 | 2019-12-02 | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112979751B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112898380B (en) * | 2019-12-02 | 2022-04-22 | 首都医科大学 | Dioxohexa-ring modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, antithrombotic activity thereof and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104211700A (en) * | 2013-06-05 | 2014-12-17 | 首都医科大学 | Novel carboline carboxylate analogues, synthesis, nano structure, antitumor activity, and applications thereof |
| CN106589056A (en) * | 2015-10-16 | 2017-04-26 | 首都医科大学 | beta-carboline-3-formyl-Trp-Lys-Lys-OBzl, synthesis and applications thereof |
| CN109134605A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GYIGSK, synthesis, activity and application |
-
2019
- 2019-12-02 CN CN201911216154.3A patent/CN112979751B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104211700A (en) * | 2013-06-05 | 2014-12-17 | 首都医科大学 | Novel carboline carboxylate analogues, synthesis, nano structure, antitumor activity, and applications thereof |
| CN106589056A (en) * | 2015-10-16 | 2017-04-26 | 首都医科大学 | beta-carboline-3-formyl-Trp-Lys-Lys-OBzl, synthesis and applications thereof |
| CN109134605A (en) * | 2017-06-16 | 2019-01-04 | 首都医科大学 | 1,1- dihydroxymethyl-tetrahydro-beta-carboline -3- formyl-GYIGSK, synthesis, activity and application |
Non-Patent Citations (2)
| Title |
|---|
| 3S-1234-四氢-β-咔啉-3-羧酸的结构修饰和抗血栓活性研究;薛宝玉等;《首都医科大学学报》;20050228;全文 * |
| The Synthesis and Immunosuppressive activities of steroid-urotoxin linkers;Wang et al.;《Bioorganic & Medicinal Chemistry》;20041231;全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112979751A (en) | 2021-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112898377B (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGE, preparation thereof, anti-inflammatory activity thereof and application thereof | |
| JP5860397B2 (en) | Tripeptide boronic acid or tripeptide boronic acid ester, preparation method and use thereof | |
| CN103450340B (en) | The antineoplastic oligopeptide that heterocyclic carboxylic acid is modified, its synthesis, antitumor action and application | |
| CA2528586A1 (en) | Cyclohexanecarboxylic acid compound | |
| CN112898381B (en) | Dioxahexacyclic modified tetrahydrocarboline-3-formyl-The-EDG, preparation, anti-inflammatory and antithrombotic activity and application thereof | |
| CN112979751B (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, anti-inflammatory activity thereof and application thereof | |
| RU2362579C1 (en) | Pharmaceutical composition on basis of peptide possessing antitumoral action | |
| EP0005658A1 (en) | Peptide derivatives analogue to encephalines, process for their preparation and their therapeutical application | |
| JP5950390B2 (en) | New mimosine derivatives | |
| CN112898380B (en) | Dioxohexa-ring modified tetrahydrocarboline-3-formyl-The-HGK, preparation thereof, antithrombotic activity thereof and application thereof | |
| JP2022524585A (en) | New peptides and their uses | |
| JP2023061959A (en) | Compound, method of producing compound, enriched extract, active fraction of enriched extract, method of producing enriched extract, method of selecting vegetal biomass for producing enriched extract, composition for treating immunological disorder, and applications thereof | |
| WO2011144054A1 (en) | Dibenzocyclooctene lignan derivatives and uses thereof in treatment of viral hepatitis | |
| CN112979667B (en) | Dioxahexacyclic modified tetrahydrocarboline-3-formyl-The, synthesis, activity and application thereof | |
| EP3272765A1 (en) | Peptide derivative for regulating thymic stromal lymphoid protein-mediated signaling and pharmaceutical composition for preventing and treating allergy and asthma diseases comprising same | |
| CA1167864A (en) | Esters of mercapto acyl-carnitines, process for their preparation and pharmaceutical compositions containing same | |
| CN112979752B (en) | Dioxane-modified tetrahydrocarboline-3-formyl-The-EDG, preparation thereof, antitumor activity thereof and application thereof | |
| CN107890569A (en) | The preparation method for the dual Brain targeting prodrug modified jointly with glucose and ascorbic acid | |
| US4666887A (en) | Intravenous or intraperitoneal administration of a tripeptide compound for treating cancer | |
| CN112010938B (en) | Acetyl RGD modified hexacyclic piperazinedione, preparation, anti-inflammatory activity and application thereof | |
| JPS59144765A (en) | 2-(1-piperazinyl)pyrimidine, manufacture and medicinal composition | |
| CN115215817B (en) | 2-aminothiazole-4-acetic acid derivative and preparation method and application thereof | |
| CN101880315A (en) | Branch oligopeptide with analgesic activity, preparation method and application thereof | |
| CN1173169A (en) | Benzene derivatives | |
| JPS5858342B2 (en) | Dopamine derivatives and medicines containing dopamine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20220422 |